跳至主要内容
临床试验/NCT01680016
NCT01680016已完成3 期

A Phase IIIb, Randomized, Open-label Study Comparing Two Different Rabies Vaccine Post-exposure Schedules (Zagreb 2-1-1 and Rabipur® Essen 1-1-1-1-1) in Chinese Children and Older Adults

Novartis Vaccines1 个研究点 分布在 1 个国家目标入组 644 人开始时间: 2012年9月最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
644
试验地点
1
主要终点
Non-inferiority in Immune Response of the Zagreb Postexposure Schedule of Rabipur to That of the Conventional Essen Postexposure Schedule of Rabipur as Measured by GMC of RVNA Titer 14 Days After First Vaccination in Children Aged ≥6 to ≤17 Years.

研究概览

简要总结

This study was designed to evaluate the safety and immunogenicity of two simulated postexposure rabies vaccination schedules (Zagreb 2-1-1 and Essen 1-1-1-1-1) in Chinese children and older adults.

详细描述

This study was designed to evaluate the safety and immunogenicity of Rabipur Zagreb (2-1-1) and Rabipur Essen (1-1-1-1-1) simulated post exposure vaccination schedules in Chinese children and older adults. Subjects randomized to Group 1 (Zagreb) will receive 4 doses of rabies vaccine Day 1 (2 doses), and on Day 8 and Day 22. Subjects randomized to Group 2 (Essen) will receive 5 doses of rabies vaccine on Days 1, 4, 8, 15, and 29. First vaccine will be administered on study Day 1.

240 children and 400 older adults, a total of 640, is planned to be enrolled into the study. Subjects will be divided further into age subsets of equal numbers within each age cohort (children: 6 to 11 years of age and 12 to 17 years of age; older adults: 51 to 60 years of age and 61 years of age and older. Within each age subset, subjects will be assigned randomly in a 1:1 ratio.

The primary objective is to establish the non-inferiority of the Rabipur Zagreb (2-1-1) schedule relative to the conventional Rabipur Essen (1-1-1-1-1) schedule based on geometric mean titers (GMC), and the secondary objective is to assess the percent of subjects with rabies virus neutralizing titer ≥ 0.5 IU/mL 14 days after the first vaccinations (study Day 15) for each schedule and age cohort

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
6 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Individuals between 6-17 years of age and 51 years of age or older
  • Individuals who were in good health
  • Provided consent, complied with study procedures and duration of follow-up

排除标准

  • Contraindications to vaccination with rabies vaccine
  • Body temperature ≥37.5◦C (axillary) within 3 days of intended study vaccination
  • Known hypersensitivity to the components of the vaccine
  • Previously received any rabies vaccine or immune globulin
  • Previous or planned treatment with antimalarial medications
  • History of psychiatric disease, immune disorder, bleeding disorder, drug/alcohol abuse within the past 2 years, malignancy
  • Female subjects who were pregnant or unwilling to practice acceptable birth control methods
  • Individuals enrolled or plans to enroll in another investigational trial

结局指标

主要结局

Non-inferiority in Immune Response of the Zagreb Postexposure Schedule of Rabipur to That of the Conventional Essen Postexposure Schedule of Rabipur as Measured by GMC of RVNA Titer 14 Days After First Vaccination in Children Aged ≥6 to ≤17 Years.

时间窗: Before vaccination (day 1) and 14 days after first vaccination (day 15)

Immunogenicity was measured as the geometric mean concentrations (GMCs) of rabies virus neutralizing antibody (RVNA) titer , evaluated using the rapid fluorescent focus inhibition test, before vaccination and 14 days after first vaccination of Rabipur as per Zagreb (2-1-1) and Essen (1-1-1-1-1) postexposure schedule.

Non-inferiority in Immune Response of the Zagreb Postexposure Schedule of Rabipur to That of the Conventional Essen Postexposure Schedule of Rabipur as Measured by GMC of RVNA Titer 14 Days After the First Vaccination in Older Adults Aged ≥51 Years

时间窗: Before vaccination (day 1) and 14 days after first vaccination (day 15).

Immunogenicity was measured as the GMCs of Rabies Virus Neutralizing Antibody (RVNA) titer , evaluated using the rapid fluorescent focus inhibition test, before vaccination and 14 days after first vaccination of Rabipur as per Zagreb (2-1-1) and Essen (1-1-1-1-1) postexposure schedule.

Number of Children Who Reported Solicited Local and Systemic Adverse Events After Any Vaccination of Rabipur

时间窗: Days 1 to 7 postvaccination

Safety was assessed as the number of children who reported solicited local and systemic adverse events from day 1 up to and including day 7 after any vaccination of Rabipur as per Zagreb (2-1-1) and Essen (1-1-1-1-1) postexposure schedule.

Number of Older Adults Who Reported Solicited Local and Systemic Adverse Events After Any Vaccination of Rabipur

时间窗: Days 1 to 7 postvaccination

Safety was assessed as the number of subjects who reported solicited local and systemic adverse events from day 1 up to and including day 7 after any vaccination of Rabipur as per Zagreb (2-1-1) and Essen (1-1-1-1-1) postexposure schedule.

Number of Older Adults Who Reported Unsolicited Adverse Events (AEs)

时间窗: from V1/day 1 (postvaccination) through V7/study termination day 43

The safety of Rabipur was assessed in terms of subjects(Older Adults) exposed to study vaccine who reported all Unsolicited AEs (including serious adverse events \[SAE\]s and AEs leading to subject withdrawal) from V1/day 1 (postvaccination) through V7/study termination day 43.

Number of Children Who Reported Unsolicited Adverse Events (AEs)

时间窗: From V1/day 1 (postvaccination) through V7/study termination day 43

The safety of Rabipur was assessed in terms of subjects(Children) exposed to study vaccine who reported all Unsolicited AEs (including serious adverse events \[SAE\]s and AEs leading to subject withdrawal) from V1/day 1 (postvaccination) through V7/study termination day 43.

次要结局

  • GMCs of RVNA Titer 42 Days After First Vaccination in Children.(Before vaccination (day 1) and 42 days after first vaccination (day 43))
  • GMCs of RVNA Titer 42 Days After the First Vaccination in Older Adults.(Before vaccination (day 1) and 42 days after first vaccination (day 43))
  • Percentages of Children With RVNA Titers ≥0.5 IU/mL 14 Days After First Vaccination of Rabipur(Before vaccination (day 1) and 14 days after first vaccination (day 15).)
  • Percentages of Older Adults With RVNA Titers ≥0.5 IU/mL 14 Days After First Vaccination of Rabipur(Before vaccination (day 1) and 14 days after first vaccination (day 15).)
  • Percentages of Children With RVNA Titers ≥0.5 IU/mL 42 Days After First Vaccination of Rabipur(Before vaccination (day 1) and 42 days after first vaccination (day 43).)
  • Percentages of Older Adults With RVNA Titers ≥0.5 IU/mL 42 Days After First Vaccination of Rabipur(Before vaccination (day 1) and 42 days after first vaccination (day 43).)

研究者

发起方
Novartis Vaccines
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验